PTPRK and central nervous system cancer: As expected, using MTT cytotoxicity assay, we observed increased sensitivity of malignant glioma cells to anticancer drugs following expression of functionally active wild-type PTPRK and little or no significant change in sensitivity with abnormal PTPRK, compared to mock cells.